At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
CERO CERo Therapeutics Holdings, Inc.
Post-Mkt 12-08 15:59:59 EST Delay
BRIEF-Cero Therapeutics Holdings Inc - Continues To Evaluate Additional Options For Up-List
Reuters  ·  12-02
BRIEF-Cero Therapeutics Holdings Inc - Continues To Evaluate Additional Options For Up-List
Cero Therapeutics Announces $14.6 Million Private Stock Sale to Institutional Investor
Reuters  ·  12-02
Cero Therapeutics Announces $14.6 Million Private Stock Sale to Institutional Investor
Cero Therapeutics Holdings Inc - Continues to Evaluate Additional Options for up-List
THOMSON REUTERS  ·  12-02
Cero Therapeutics Holdings Inc - Continues to Evaluate Additional Options for up-List
CERo Therapeutics Cut to Hold From Buy by D. Boral Capital
Dow Jones  ·  11-19
CERo Therapeutics Cut to Hold From Buy by D. Boral Capital
Cero Therapeutics Holdings Inc. Announces Date for 2025 Special Meeting of Stockholders
Reuters  ·  11-17
Cero Therapeutics Holdings Inc. Announces Date for 2025 Special Meeting of Stockholders
CERo Therapeutics Advances Phase 1 AML Trial with Higher Dosing of CER-1236
Reuters  ·  11-05
CERo Therapeutics Advances Phase 1 AML Trial with Higher Dosing of CER-1236
Cero Therapeutics Presents Promising Phase 1 Data for Lead Immunotherapy CER-1236 in AML
Reuters  ·  11-04
Cero Therapeutics Presents Promising Phase 1 Data for Lead Immunotherapy CER-1236 in AML
Cero Therapeutics announces listing on OTC Markets
TIPRANKS  ·  11-03
Cero Therapeutics announces listing on OTC Markets
Cero Therapeutics discloses Nasdaq Panel listing determination
TIPRANKS  ·  10-30
Cero Therapeutics discloses Nasdaq Panel listing determination
Cero Therapeutics Shares to Be Suspended from Nasdaq Trading October 31
Reuters  ·  10-30
Cero Therapeutics Shares to Be Suspended from Nasdaq Trading October 31
CERo Therapeutics Advances Phase 1 Trial of CER-1236 in AML with Third Patient Dose
Reuters  ·  10-21
CERo Therapeutics Advances Phase 1 Trial of CER-1236 in AML with Third Patient Dose
Cero Therapeutics Announces Third Dose for Patient in Phase 1 Clinical Trial of Cer-1236 in Aml
THOMSON REUTERS  ·  10-21
Cero Therapeutics Announces Third Dose for Patient in Phase 1 Clinical Trial of Cer-1236 in Aml
CERo Therapeutics Holdings (CERO) Receives a Buy from Maxim Group
TIPRANKS  ·  10-16
CERo Therapeutics Holdings (CERO) Receives a Buy from Maxim Group
Cero Therapeutics Holdings Inc. Announces $7 Million Private Placement of Series E Convertible Preferred Stock
Reuters  ·  10-14
Cero Therapeutics Holdings Inc. Announces $7 Million Private Placement of Series E Convertible Preferred Stock
BUZZ-U.S. STOCKS ON THE MOVE-Keurig Dr Pepper, Ardelyx, Vertiv
Reuters  ·  10-14
BUZZ-U.S. STOCKS ON THE MOVE-Keurig Dr Pepper, Ardelyx, Vertiv
BUZZ-CERo climbs after blood cancer drug trial moves to next phase
Reuters  ·  10-13
BUZZ-CERo climbs after blood cancer drug trial moves to next phase
Cero Therapeutics Completes First Cohort of Phase 1 Trial for CER-1236 in AML, Initiates Next Dose Escalation
Reuters  ·  10-13
Cero Therapeutics Completes First Cohort of Phase 1 Trial for CER-1236 in AML, Initiates Next Dose Escalation
Cero Therapeutics Announces Completion of First Cohort of Phase 1 Clinical Trial of Cer-1236 in Aml
THOMSON REUTERS  ·  10-13
Cero Therapeutics Announces Completion of First Cohort of Phase 1 Clinical Trial of Cer-1236 in Aml
Cero Therapeutics Holdings Inc - Asserts It Is Not for Sale or Seeking Partnerships
THOMSON REUTERS  ·  10-13
Cero Therapeutics Holdings Inc - Asserts It Is Not for Sale or Seeking Partnerships
Cero Therapeutics ‘open’ to takeover bids, Axios reports
TIPRANKS  ·  10-11
Cero Therapeutics ‘open’ to takeover bids, Axios reports

Introduction

Company Name.
CERo Therapeutics Holdings, Inc.
Affiliated Markets:
OTCQB
Listing Date:
--
Main Business:
CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies. The company was incorporated in 2021 and is based in South San Francisco, California.
Issue price:
--